| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma
|
Fiala, Mark A.
|
|
2019
|
19 |
9 |
p. e521-e525
|
artikel
|
| 2 |
Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights
|
Venugopal, Sangeetha
|
|
2019
|
19 |
9 |
p. 545-554
|
artikel
|
| 3 |
Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma
|
Wang, Ying
|
|
2019
|
19 |
9 |
p. e545-e550
|
artikel
|
| 4 |
Editorial Board
|
|
|
2019
|
19 |
9 |
p. A4-A5
|
artikel
|
| 5 |
Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis
|
Bhutani, Divaya
|
|
2019
|
19 |
9 |
p. 555-559
|
artikel
|
| 6 |
Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome
|
Fakhri, Bita
|
|
2019
|
19 |
9 |
p. e532-e535
|
artikel
|
| 7 |
Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up
|
Ćojbašić, Irena
|
|
2019
|
19 |
9 |
p. e526-e531
|
artikel
|
| 8 |
High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma
|
Mirza, Abu-Sayeef
|
|
2019
|
19 |
9 |
p. e513-e520
|
artikel
|
| 9 |
High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy
|
Beltran, Brady E.
|
|
2019
|
19 |
9 |
p. e551-e557
|
artikel
|
| 10 |
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Shah, Jatin
|
|
2019
|
19 |
9 |
p. 570-578.e1
|
artikel
|
| 11 |
POEMS Syndrome: Indian Experience From a Tertiary-Care Institute
|
Pramanik, Raja
|
|
2019
|
19 |
9 |
p. e536-e544
|
artikel
|
| 12 |
Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis
|
Austin, Matthew
|
|
2019
|
19 |
9 |
p. 593-597
|
artikel
|
| 13 |
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
|
Gassiot, Susanna
|
|
2019
|
19 |
9 |
p. 585-592.e1
|
artikel
|
| 14 |
Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia
|
Tabchi, Samer
|
|
2019
|
19 |
9 |
p. 560-569
|
artikel
|
| 15 |
SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents
|
Madduri, Deepu
|
|
2019
|
19 |
9 |
p. 537-544
|
artikel
|
| 16 |
Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
|
Grunwald, Michael R.
|
|
2019
|
19 |
9 |
p. 579-584.e1
|
artikel
|
| 17 |
Table of Contents
|
|
|
2019
|
19 |
9 |
p. A6-A7, A12-A13
|
artikel
|
| 18 |
Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation
|
Peterson, Jess F.
|
|
2019
|
19 |
9 |
p. 598-602
|
artikel
|
Tijdschrift beschrijving